TD Cowen analyst Tara Bancroft has maintained their bullish stance on TCRX stock, giving a Buy rating on March 7.
Tara Bancroft’s rating is based on the promising clinical data and future potential of TScan Therapeutics. The updated Phase I ALLOHA trial data for TSC-100/101 showed a significant improvement in event-free survival and a lower probability of relapse compared to the control group. This suggests a strong efficacy profile for the treatment in patients with AML, ALL, or MDS undergoing transplant.
Furthermore, TScan’s financial position is solid, with sufficient cash reserves to support ongoing developments. The upcoming pivotal trial, expected to start in the second half of 2025, and the anticipated multiplex data from the solid tumor program represent significant growth opportunities. These factors combined contribute to the positive outlook and the Buy rating for TScan Therapeutics.
Bancroft covers the Healthcare sector, focusing on stocks such as Geron, Protagonist Therapeutics, and TG Therapeutics. According to TipRanks, Bancroft has an average return of -8.2% and a 26.21% success rate on recommended stocks.
In another report released on March 7, Barclays also maintained a Buy rating on the stock with a $3.00 price target.